BJU Int

1. MUSI G, Mistretta FA, Ivanova M, de Cobelli O, et al
   Evaluation of margins during radical prostatectomy: confocal microscopy vs frozen section analysis.
   BJU Int. 2024;134:773-780.
   

   >> Share

   
   
2. LIU J, Cundy TP, Woon DTS, Desai N, et al
   A systematic review on artificial intelligence evaluating PSMA PET scan for intraprostatic cancer.
   BJU Int. 2024;134:714-722.
   

   >> Share

   
   
3. LI T, Graham PL, Cao B, Nalavenkata S, et al
   Accuracy of MRI in detecting seminal vesicle invasion in prostate cancer: a systematic review and meta-analysis.
   BJU Int. 2024 Oct 22. doi: 10.1111/bju.16547.
   

   >> Share

   
   

   
   BMC Urol

4. LI C, Jin Z, Wei C, Dai G, et al
   Comparison in prostate cancer diagnosis with PSA 4-10 ng/mL: radiomics-based model VS. PI-RADS v2.1.
   BMC Urol. 2024;24:233.
   

   >> Share

   
   

   
   Br J Cancer

5. RAHMAN R, Rahaman MH, Hanson AR, Choo N, et al
   Author Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.
   Br J Cancer. 2024 Oct 24. doi: 10.1038/s41416-024-02862.
   

   >> Share

   
   

   
   Clin Cancer Res

6. STOPSACK KH, Vijai J, Conry M, Berchuck JE, et al
   Germline DNA damage repair variants and prognosis of patients with high-risk or metastatic prostate cancer.
   Clin Cancer Res. 2024 Oct 25. doi: 10.1158/1078-0432.CCR-24-2483.
   

   >> Share

   
   

   
   Eur J Radiol

7. KLEIBURG F, de Geus-Oei LF, Luelmo SAC, Spijkerman R, et al
   PSMA PET/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients.
   Eur J Radiol. 2024;181:111774.
   

   >> Share

   
   

   
   Eur Urol

8. TWILT JJ, Saha A, Bosma JS, van Ginneken B, et al
   Evaluating Biparametric Versus Multiparametric Magnetic Resonance Imaging for Diagnosing Clinically Significant Prostate Cancer: An International, Paired, Noninferiority, Confirmatory Observer Study.
   Eur Urol. 2024 Oct 21:S0302-2838(24)02640-X. doi: 10.1016/j.eururo.2024.
   

   >> Share

   
   
9. VANDERWEELE DJ, Hussain M
   Management Decisions for Metastatic Castration-resistant Prostate Cancer in 2024.
   Eur Urol. 2024 Oct 19:S0302-2838(24)02646-0. doi: 10.1016/j.eururo.2024.
   

   >> Share

   
   
10. EVANGELISTA L, Cecchi L, Zucali PA
    Advancing Prostate Cancer Care: Prostate-specific Membrane Antigen-based Radioligand Therapy at the Forefront.
    Eur Urol. 2024 Oct 19:S0302-2838(24)02645-9. doi: 10.1016/j.eururo.2024.
    

    >> Share

    
    
11. FENDLER WP, Grunwald V, Herrmann K, Hadaschik BA, et al
    Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker: Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate Cancer.
    Eur Urol. 2024 Oct 19:S0302-2838(24)02648-4. doi: 10.1016/j.eururo.2024.
    

    >> Share

    
    

    
    Magn Reson Imaging

12. STAROBINETS O, Simko JP, Gibbons M, Kurhanewicz J, et al
    The impact of benign tissue within cancerous regions in the prostate: Characterizing sparse and dense prostate cancers on whole-mount histopathology and on multiparametric MRI.
    Magn Reson Imaging. 2024 Sep 9:110233. doi: 10.1016/j.mri.2024.110233.
    

    >> Share

    
    

    
    Oncogene

13. WANG K, Chen M, Yan S, Han Y, et al
    Zinc ions activate AKT and promote prostate cancer cell proliferation via disrupting AKT intramolecular interaction.
    Oncogene. 2024 Oct 23. doi: 10.1038/s41388-024-03195.
    

    >> Share

    
    

    
    PLoS One

14. KILERCIK M, Ozgur E, Sahin S, Sen Dogan B, et al
    Detection of circulating tumor cells in non-metastatic prostate cancer through integration of a microfluidic CTC enrichment system and multiparametric flow cytometry.
    PLoS One. 2024;19:e0312296.
    

    >> Share

    
    
15. SANCHEZ-FERNANDEZ D, Eguibar A, Lopez C, Cuesta AM, et al
    Effect of 5beta-dihydrotestosterone on vasodilator function and on cell proliferation.
    PLoS One. 2024;19:e0312080.
    

    >> Share

    
    
16. LI R, Chen X, Wang Y
    Adverse events analysis of Relugolix (Orgovyx(R)) for prostate cancer based on the FDA Adverse Event Reporting System (FAERS).
    PLoS One. 2024;19:e0312481.
    

    >> Share

    
    
17. WANG X, Jiang R, Shen J, Chen S, et al
    Transitions in metabolic syndrome and metabolic obesity status over time and risk of urologic cancer: A prospective cohort study.
    PLoS One. 2024;19:e0311492.
    

    >> Share

    
    

    
    Prostate

18. SHUKLA S, Osumi T, Al-Toubat M, Serrano S, et al
    Protein kinase D1 mitigation against etoposide induced DNA damage in prostate cancer is associated with increased alpha-Catenin.
    Prostate. 2024 Oct 20. doi: 10.1002/pros.24812.
    

    >> Share

    
    
19. ERTL IE, Lemberger U, Rajwa P, Petrov P, et al
    Low SMARCD3 expression is associated with poor prognosis in patients with prostate cancer.
    Prostate. 2024 Oct 23. doi: 10.1002/pros.24815.
    

    >> Share

    
    
20. DI BELLO F, Jannello LMI, Baudo A, de Angelis M, et al
    Life Expectancy in High-Grade Incidental Prostate Cancer Patients Versus Population-Based Controls According to Treatment Type.
    Prostate. 2024 Oct 24:e24816. doi: 10.1002/pros.24816.
    

    >> Share

    
    

    
    Urology

21. LEPOR H, Rapoport E, Tafa M, Gogaj R, et al
    5-year Oncologic Outcomes Following Primary Partial Gland Cryo-Ablation (PPGCA) Prospective Cohort Study of Men with Intermediate-Risk Prostate Cancer.
    Urology. 2024 Oct 22:S0090-4295(24)00925-7. doi: 10.1016/j.urology.2024.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share